Feb 1, 2021
Legend Biotech announces BCMA CAR-T Therapy Cilta-cel accepted for accelerated assessment in Europe for the treatment of relapsed and/or refractory multiple myeloma
Legend Biotech announces BCMA CAR-T Therapy Cilta-cel accepted for accelerated assessment in Europe for the treatment of relapsed and/or refractory multiple myeloma
SOMERSET, N.J. — (BUSINESS WIRE) — Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has accepted a request for an…
View On WordPress